NASDAQ · COYA
Healthcare · Biotechnology
$4.87
Up+$0.01 (+0.21%)
Updated Aug 23, 2026, 6:08 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
COYA closed at $4.87 after 20 trading sessions, up 14.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $4.90 | $4.95 | $4.805 | $4.87 | 70.95K |
| Aug 20, 2026 | $5.00 | $5.00 | $4.73 | $4.86 | 59.52K |
| Aug 19, 2026 | $4.96 | $5.10 | $4.95 | $4.97 | 118.87K |
| Aug 18, 2026 | $4.65 | $4.93 | $4.65 | $4.92 | 106.65K |
| Aug 17, 2026 | $4.81 | $4.81 | $4.63 | $4.67 | 67.28K |
| Aug 14, 2026 | $4.70 | $4.85 | $4.55 | $4.79 | 113.56K |
| Aug 13, 2026 | $4.72 | $4.82 | $4.67 | $4.67 | 97.49K |
| Aug 12, 2026 | $4.83 | $4.83 | $4.67 | $4.69 | 85.59K |
| Aug 11, 2026 | $4.62 | $4.85 | $4.52 | $4.80 | 130.18K |
| Aug 10, 2026 | $4.80 | $4.80 | $4.57 | $4.64 | 181.09K |
| Aug 7, 2026 | $4.71 | $4.8391 | $4.65 | $4.81 | 141.84K |
| Aug 6, 2026 | $4.555 | $4.695 | $4.52 | $4.58 | 249.79K |
| Aug 5, 2026 | $4.61 | $4.6714 | $4.485 | $4.55 | 99.7K |
| Aug 4, 2026 | $4.45 | $4.65 | $4.43 | $4.57 | 145.68K |
| Aug 3, 2026 | $4.24 | $4.46 | $4.13 | $4.43 | 116.7K |
| Jul 31, 2026 | $4.08 | $4.22 | $3.995 | $4.19 | 179.95K |
| Jul 30, 2026 | $3.94 | $4.12 | $3.92 | $4.08 | 151.36K |
| Jul 29, 2026 | $4.00 | $4.15 | $3.855 | $3.87 | 144.31K |
| Jul 28, 2026 | $4.26 | $4.29 | $3.985 | $4.00 | 203.22K |
| Jul 27, 2026 | $4.33 | $4.405 | $4.24 | $4.265 | 81.17K |
The latest Smart Investors Daily articles mentioning COYA.
COYA research
Company profile and research snapshot.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 12, 2026 | Chardan Capital | Buy | — |
| Jun 12, 2026 | Chardan Capital | Buy | — |
| Jun 5, 2026 | Roth Capital | Buy | — |
| Apr 10, 2026 | D. Boral Capital | Buy | — |
| Mar 23, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
Coya Therapeutics (NASDAQ:COYA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.34) by 17.65 percent. This is a 22.22 percent increase over losses of $(0.36) per share
SeekingAlpha · Jul 25, 2026
Greenlight Capital's 13F portfolio rose from $2.85B to $3.19B in Q1 2026, outperforming the S&P 500 with a 6.5% return vs. -4.4%. Read more on the portfolio here.
Benzinga · Jun 18, 2026
Poster Title: ALSTARS: A Precision Immunomodulatory Phase 2 Trial Of Coya 302 Targeting Regulatory T Cells And Neuroinflammation In ALSAuthors: Tyrell J. Simkins, DO, PhD; Fred Grossman, DO; Stanley Appel, MD; Karen
Benzinga · Jun 8, 2026
Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces the initiation of the blinded extension phase of
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning COYA.
